Kymera in the News

Kymera Therapeutics recently shared promising results from the phase 1 clinical trial of its lead program, KT-474, marking a significant milestone in the field of targeted protein degradation (TPD).

Kymera Therapeutics’ degrader KT-474 has shown promise for treating two inflammatory skin conditions in an early clinical trial. The success suggests that these compounds could be used to treat nonlethal, chronic conditions, where there is a high bar for tolerability.

Cells have intricate mechanisms to remove damaged or mis-expressed proteins that could be deleterious to cellular function. This process is mediated by a process called ubiquitination, mediated by a special class of proteins called E3 ligases. Ubiquitin is the tag that’s added that signals that a protein should be moved to the biochemical garbage can. Dr. Juliet WIlliams of Kymera describes how their company has used modeling and A.I. to design molecular linkers that connect a protein that needs to be degraded with the machinery to tag it for destruction.

The company has a program called Kymera Cares, an effort that allows employees to give back, volunteer, and fundraise for organizations helping local communities throughout the greater Boston area as well as patients and their support systems.

The FDA has granted fast track designation to KT-333 for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) and relapsed/refractory peripheral T-cell lymphoma (PTCL).

Kymera Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for KT-333 to treat Relapsed/Refractory (R/R) Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL).

A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research.

Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement

With more attention being paid to work-life balance and employee burnout, a slower summer may not be a bad thing. The biopharma industry in particular is often go-go-go, but industry leaders still look for ways to stop and smell the roses while keeping innovation on track.

Sanofi will advance an experimental inflammatory disease drug into Phase 2 clinical testing after its biotechnology company partner Kymera Therapeutics reported Wednesday what it described as encouraging results from a small study.